Data Rules All in RYAH Group's IoT Solution for Plant-Based Medicine

Photo by Franki Chamaki on Unsplash

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

The advent of plant-based medicine has brought with it a mixture of excitement and complications.

On the one hand, decades of anti-plant propaganda and pseudo-science labels are finally morphing into scientific merit and consumer credibility. This is valuable news for the 40% of people who consistently fall victim to the side effects of mainstream drugs, and even more so for the 33% of people whose symptoms return after prolonged drug treatment.

On the other hand, a lack of admissible data and solutions for plant-based medicine drives regulatory complications and creates obstacles for researchers. The patient’s preference for specific plant-based medicine, treatment protocols and dosage requirements are all swept under the rug. Without uniform medical feedback, researchers and doctors are unable to optimize treatment, and patients suffer. 

RYAH Group Inc. RYAH aims to change this. Using its internet of things (IoT) infrastructure, the company is creating a data-driven digital platform that gives both patients and doctors control over the plant-medicine experience. Serving alongside a suite of hardware products, the company says its artificial intelligence and machine-learning technologies provide consistent and structured data for researchers, users and clinics.

Why Plant-Based Medicine Needs Big Data

Operating at the crossroads between Big Data and IoT, RYAH finds itself at the center of two markets experiencing aggressive growth. The IoT market alone is expected to reach $1.6 trillion by 2025, while Big Data is expected to surpass $116 billion in 2027.

Industry leaders like International Business Machines Corp. IBM and Globus Medical Inc. GMED have already seen the opportunity in the Big Data niche of the healthcare sector, each emerging with its unique solution. IBM’s Watson Health, for example, helps clinicians and health system leaders optimize care delivery and performance for patients.

RYAH’s IoT system is built to achieve the same goal in the plant-medicine space, where a lack of data is blurring the lines for what regulators deem appropriate for research. The journey begins with the Smart Product Suite — a group of IoT hardware products that provide precise control over nuances like dosage and temperature when consuming plant-based medicine. These data points, alongside responses from the patients about their experience, are sent over to the RYAH Cloud, where they are aggregated, catalogued and analyzed.

The result of the process is a uniform, insightful and closed-loop operation that allows artificial intelligence and machine-learning technologies to form important generalizations and insights.

And this is where RYAH says the value truly lies. Since the legalization of cannabis for both medical and recreational use and psilocybin for medicinal purposes, an array of businesses have sprung up to capture market leadership status. But data collection and interpretation have not been standardized, leaving regulators, researchers and even patients potentially unaware of optimization and safety information.

RYAH says its all-in-one IoT solution provides the tools and infrastructure to standardize data collection within the plant-medicine space. With it, the hope is that the plant-based medicine industry can move better, smarter and quicker.

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.